183 related articles for article (PubMed ID: 33618687)
1. Changes in cerebrospinal fluid interleukin-10 levels display better performance in predicting disease relapse than conventional magnetic resonance imaging in primary central nervous system lymphoma.
Zhang Y; Zou D; Yin J; Zhang L; Zhang X; Wang W; Zhang M; Zhou D; Zhang W
BMC Cancer; 2021 Feb; 21(1):183. PubMed ID: 33618687
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal Fluid IL-10 and IL-10/IL-6 as Accurate Diagnostic Biomarkers for Primary Central Nervous System Large B-cell Lymphoma.
Song Y; Zhang W; Zhang L; Wu W; Zhang Y; Han X; Yang C; Zhang L; Zhou D
Sci Rep; 2016 Dec; 6():38671. PubMed ID: 27924864
[TBL] [Abstract][Full Text] [Related]
3. The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients.
Nguyen-Them L; Costopoulos M; Tanguy ML; Houillier C; Choquet S; Benanni H; Elias-Shamieh R; Armand M; Faivre G; Glaisner S; Malak S; Vargaftig J; Hoang-Xuan K; Ahle G; Touitou V; Cassoux N; Davi F; Merle-Béral H; Le Garff-Tavernier M; Soussain C;
Eur J Cancer; 2016 Jul; 61():69-76. PubMed ID: 27156226
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL).
Sasayama T; Nakamizo S; Nishihara M; Kawamura A; Tanaka H; Mizukawa K; Miyake S; Taniguchi M; Hosoda K; Kohmura E
Neuro Oncol; 2012 Mar; 14(3):368-80. PubMed ID: 22156547
[TBL] [Abstract][Full Text] [Related]
5. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M
Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study.
Li J; Tang X; Luo X; Liu L; Li D; Yang L
Ann Hematol; 2023 Aug; 102(8):2153-2163. PubMed ID: 37289220
[TBL] [Abstract][Full Text] [Related]
7. [Primary central nervous system lymphoma: a case report and evaluation of the diagnostic value of IL-10 level in the cerebrospinal fluid].
Mishima T; Tsuboi Y; Enomoto T; Higuchi MA; Tsugawa J; Yamada T; Tanaka T; Tsugu H; Hayashi H; Nabeshima K
Brain Nerve; 2012 Nov; 64(11):1347-51. PubMed ID: 23131747
[TBL] [Abstract][Full Text] [Related]
8. Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial.
Tabouret E; Houillier C; Martin-Duverneuil N; Blonski M; Soussain C; Ghesquières H; Houot R; Larrieu D; Soubeyran P; Gressin R; Gyan E; Chinot O; Taillandier L; Choquet S; Alentorn A; Leclercq D; Omuro A; Tanguy ML; Hoang-Xuan K
Neuro Oncol; 2017 Mar; 19(3):422-429. PubMed ID: 27994065
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system.
Sasagawa Y; Akai T; Tachibana O; Iizuka H
J Neurooncol; 2015 Jan; 121(1):177-83. PubMed ID: 25258254
[TBL] [Abstract][Full Text] [Related]
10. Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.
Thaler FS; Laurent SA; Huber M; Mulazzani M; Dreyling M; Ködel U; Kümpfel T; Straube A; Meinl E; von Baumgarten L
Neuro Oncol; 2017 Nov; 19(12):1618-1627. PubMed ID: 28521029
[TBL] [Abstract][Full Text] [Related]
11. Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.
Patel MP; Kirkpatrick JP; Johnson MO; Healy P; Herndon JE; Lipp ES; Miller ES; Desjardins A; Randazzo D; Friedman HS; Ashley DM; Peters KB
J Neurooncol; 2020 Apr; 147(2):477-483. PubMed ID: 32140975
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of cerebrospinal fluid EBV-DNA and IL-10 as markers for in vivo diagnosis of AIDS-related primary central nervous system lymphoma.
De Luca A; Antinori A; Cingolani A; Larocca LM; Linzalone A; Ammassari A; Scerrati M; Roselli R; Tamburrini E; Ortona L
Br J Haematol; 1995 Aug; 90(4):844-9. PubMed ID: 7669663
[TBL] [Abstract][Full Text] [Related]
13. Cell-Free DNA in Cerebrospinal Fluid Complements the Monitoring Value of Interleukin-10 in Newly Diagnosed Primary Central Nervous System Lymphoma.
Wang W; Zou D; Zhuang Z; Zhang X; Zhang L; Yin J; Jia C; Yuan L; Cai H; Zhang Y; Wang X; Zhang M; Zhou D; Zhang W
J Oncol; 2023; 2023():5808731. PubMed ID: 36644235
[TBL] [Abstract][Full Text] [Related]
14. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
15. The diagnostic role and dynamic changes in cerebrospinal fluid neopterin during treatment of patients with primary central nervous system lymphoma.
Geng M; Xiao H; Liu J; Song Y; Fu P; Cheng X; Zhang J; Wang G
Cancer Med; 2018 Aug; 7(8):3889-3898. PubMed ID: 29982995
[TBL] [Abstract][Full Text] [Related]
16. Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse.
Fossard G; Ferlay C; Nicolas-Virelizier E; Rey P; Ducray F; Jouanneau E; Faurie P; Belhabri A; Sunyack MP; Chassagne-Clément C; Thiesse P; Sebban C; Biron P; Blay JY; Ghesquières H
Eur J Cancer; 2017 Feb; 72():12-19. PubMed ID: 28012348
[TBL] [Abstract][Full Text] [Related]
17. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma.
Rubenstein JL; Wong VS; Kadoch C; Gao HX; Barajas R; Chen L; Josephson SA; Scott B; Douglas V; Maiti M; Kaplan LD; Treseler PA; Cha S; Hwang JH; Cinque P; Cyster JG; Lowell C
Blood; 2013 Jun; 121(23):4740-8. PubMed ID: 23570798
[TBL] [Abstract][Full Text] [Related]
18. Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma.
Whitcup SM; Stark-Vancs V; Wittes RE; Solomon D; Podgor MJ; Nussenblatt RB; Chan CC
Arch Ophthalmol; 1997 Sep; 115(9):1157-60. PubMed ID: 9298057
[TBL] [Abstract][Full Text] [Related]
19. Tumor-Associated Macrophages Associate with Cerebrospinal Fluid Interleukin-10 and Survival in Primary Central Nervous System Lymphoma (PCNSL).
Sasayama T; Tanaka K; Mizowaki T; Nagashima H; Nakamizo S; Tanaka H; Nishihara M; Mizukawa K; Hirose T; Itoh T; Kohmura E
Brain Pathol; 2016 Jul; 26(4):479-87. PubMed ID: 26314692
[TBL] [Abstract][Full Text] [Related]
20. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.
Langner-Lemercier S; Houillier C; Soussain C; Ghesquières H; Chinot O; Taillandier L; Soubeyran P; Lamy T; Morschhauser F; Benouaich-Amiel A; Ahle G; Moles-Moreau MP; Moluçon-Chabrot C; Bourquard P; Damaj G; Jardin F; Larrieu D; Gyan E; Gressin R; Jaccard A; Choquet S; Brion A; Casasnovas O; Colin P; Reman O; Tempescul A; Marolleau JP; Fabbro M; Naudet F; Hoang-Xuan K; Houot R
Neuro Oncol; 2016 Sep; 18(9):1297-303. PubMed ID: 26951382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
